Paul Donnellan
Overview
Explore the profile of Paul Donnellan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nahm S, Kiely B, OConnell R, Lee Y, Davis A, Avall-Lundqvist E, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100030.
PMID: 39878283
Objective: We evaluated the accuracy of oncologists' estimates of expected survival time in recurrent ovarian cancer. Methods: Oncologists estimated expected survival time at baseline for each patient, who were then...
2.
Sultan S, Acharya Y, Donnellan P, Hynes N, Kerin M, Soliman O
Eur Heart J Case Rep
. 2024 Jun;
8(4):ytae169.
PMID: 38887778
Background: Tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) inhibitor pathway with immune checkpoint blockade have shown promising outcomes in managing metastatic renal cancer. However, they increase the...
3.
Roncolato F, King M, OConnell R, Lee Y, Joly F, Hilpert F, et al.
Gynecol Oncol
. 2024 Feb;
185:128-137.
PMID: 38412736
Objective: To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). Methods: We analysed baseline...
4.
Flynn C, Liu S, Byrne B, Ralph J, Paz G, Anwar S, et al.
Case Rep Oncol
. 2023 Oct;
16(1):652-661.
PMID: 37900799
Apalutamide is a novel nonsteroidal androgen receptor inhibitor that has been shown to improve outcomes for patients with nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer when combined with...
5.
McDonnell T, Waldron D, Collins C, Kennedy G, Murphy D, Lannon C, et al.
BMJ Support Palliat Care
. 2023 Jul;
13(e3):e977-e980.
PMID: 37402539
No abstract available.
6.
McVeigh T, Sweeney K, Brennan D, McVeigh U, Ward S, Strydom A, et al.
Fam Cancer
. 2022 Aug;
22(2):135-149.
PMID: 36029389
In the Republic of Ireland (ROI), BRCA1/BRCA2 genetic testing has been traditionally undertaken in eligible individuals, after pre-test counselling by a Clinical Geneticist/Genetic Counsellor. Clinical Genetics services in ROI are...
7.
Lee Y, King M, OConnell R, Lanceley A, Joly F, Hilpert F, et al.
Int J Gynecol Cancer
. 2022 Jan;
32(6):761-768.
PMID: 35086926
Objective: The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum...
8.
OMahony C, Murphy K, OBrien G, Aherne J, Hanan T, Mullen L, et al.
Eur J Oncol Nurs
. 2020 Oct;
49:101842.
PMID: 33126156
Purpose: Ireland's Sláintecare health plan is placing an increased focus on primary care. A community oncology nursing programme was developed to train community nurses to deliver care in the community....
9.
Cullivan S, Bruzzi J, McHale T, Shatwan R, Donnellan P, Breen D
ERJ Open Res
. 2019 Dec;
5(4).
PMID: 31803770
http://bit.ly/32baZvo.
10.
Gullo G, Eustace A, Canonici A, Collins D, Kennedy M, Grogan L, et al.
Ther Adv Med Oncol
. 2019 Aug;
11:1758835919864236.
PMID: 31384312
Background: Combining bevacizumab and chemotherapy produced superior response rates compared with chemotherapy alone in metastatic breast cancer. As bevacizumab may cause hypertension (HTN) and increase the risk of cardiac failure,...